https://www.selleckchem.com/pr....oducts/n-ethylmaleim
On univariate and multivariate analyses, the TP53 signature status was an independent predictor of RFS. RFS among patients with TP53 mutant signature was significantly shorter than that among those with TP53 wild-type signature in a cohort of estrogen receptor-positive breast cancer. Although a difference was not significant, no recurrent cases was observed in TP53 wild-type signature group in triple negative breast cancer. This simple and precise diagnostic system to determine TP53 signature status may help in prognostic a
Like
Comment
Share
